The Journal of Clinical Endocrinology & Metabolism · 2004 · 32 citations · 44 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyNeoplasiaCancer ProgressionGastrointestinal Stromal TumorsMalignant NeoplasmsOncogenic Signaling PathwaysThyroid CancerTyrosine Kinase InhibitorsBcr-abl InhibitorsBcr-abl1 Fusion GeneChronic Myeloid Leukemia TherapyCurative InterventionCurative TherapyMetastatic Gastrointestinal Stromal TumorsProtein Tyrosine PhosphorylationTyrosine Kinase Inhibition
Imatinib mesylate is remarkably effective in treating chronic myeloid leukemia and metastatic gastrointestinal stromal tumors. Meanwhile, anaplastic thyroid carcinoma (ATC) remains a fatal malignancy for which there are currently no effective curative interventions. In chronic myeloid leukemia and gastrointestinal stromal tumors, imatinib inhibits the constitutive tyrosine kinase activity of BCR-ABL and c-KIT, respectively. Reports suggest that imatinib may also be effective against ABL and platelet-derived growth factor receptor kinase-dependent pathological conditions. These mechanisms provide a wide scope of possible clinical applications for the drug. Potentially, diseases instigated by constitutive kinase activity that can be inhibited with imatinib should be treatable with this drug. We evaluated the effects of imatinib on the viability, cycling, and tyrosine phosphorylation of ATC cells in vitro. Our data indicate that imatinib has negligible antineoplastic activity against ATC cell lines within established therapeutically useful concentrations. No constitutive kinase activity was detected in these cell lines that could be exploited as a therapeutic target by imatinib. We conclude that imatinib mesylate monotherapy would not be effective in ATC patients. Current preclinical data do not warrant future clinical studies of imatinib monotherapy for ATC.
44
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.8K citations
Medicine, Hematology, Oncology +14
Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text
Medicine, Hematology, Oncology +17